Csl Behring Gmbh

Csl Limited

Csl Behring Lengnau Ag

Zlb Behring Gmbh

Stefan Schulte

Thomas Weimer

Hubert Metzner

Sabine Zollner

Sabine Pestel

Carsten Horn

Gerhard Dickneite

Ulrich Kronthaler

Hans-Peter Hauser

Marc Nolte

Wiegand Lang

Ingo Pragst

Uwe Liebing

Kay Hofmann

Hans-Wilhelm Beltz

Uwe Kalina

Matthias Pelzing

Michael Moses

Gerhardt Kumpe

Hans-Arnold Stoehr

Rolf Spirig

Stefan Zeitler

Holger Lind

Volker Gawantka

Wilfried Wormsbaecher

Wilfried Wormsbächer

Annette Feussner

Stefan Schmidbauer

Wilfried Wormsbacher

Karlheinz Enssle

Bernhard Nieswandt

Steve Dower

Christoph Kleinschnitz

Joerg Lemmer

Guido Stoll

Natascha Mayer

Manfred Juraschek

Jörg Lemmer

The invention pertains to a polypeptide comprising a truncated von Willebrand Factor (VWF) and a half-life extending moiety, for use in the treatment of a blood coagulation disorder, said treatment comprising administering the polypeptide to a subject having a blood coagulation disorder and having endogenous Factor VIII (FVIII), wherein the activity level of endogenous FVIII in said subject before treatment with said polypeptide is reduced relative to the activity level of FVIII in normal human plasma (NHP) provided that the activity level of endogenous FVIII in said subject is at least 0.5% of the activity level of endogenous FVIII in normal human plasma (NHP), wherein the polypeptide is capable of binding to endogenous FVIII and wherein the endogenous FVIII level is increased following administration of said polypeptide.

Truncated von Willebrand Factor polypeptides for treating hemophilia

The present invention provides modified von Willebrand Factor molecules, methods for their preparation and uses thereof. The invention further provides pharmaceutical compositions for treating coagulation disorders.

Methods for preparing modified von Willebrand Factor

The present disclosure relates to a method for increasing the stability of a Factor VIII molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the Factor VIII molecule into a first fragment comprising essentially the A1 domain and the A2 domain and a second fragment comprising essentially the A3 domain, the C1 domain and the C2 domain throughout manufacturing the Factor VIII molecule. The disclosure further pertains to a method for improving the bioavailability of Factor VIII after intravenous and non-intravenous injection.

Method for improving the stability of purified Factor VIII after reconstitution

The invention relates to a modified VWF molecule for use in the treatment of a blood coagulation disorder.

Modified von Willebrand factor having improved half-life

Methods for preparing modified von Willebrand factor

The invention relates to a polypeptide comprising a truncated von Willebrand Factor (VWF) for use in the treatment of a blood coagulation disorder, wherein the polypeptide carries a half-life extending moiety and is administered in molar excess over Factor VIII and/or endogenous VWF.

Truncated von Willebrand factor polypeptides for treating hemophilia

Method for improving the stability of purified factor VIII after reconstitution

The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.

Sugar compositions for treating hemophilia A and/or Von Willebrand disease

An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure.

Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces

The present invention relates to a covalent complex of von Willebrand Factor (VWF) and Factor VIII, wherein the complex is modified such that it has an extended half-life in vivo. The invention further relates to a method of producing the complex, as well as the therapeutic or prophylactic use of the complex for treating or preventing bleeding events.

Covalent complex of von Willebrand Factor and factor VIII, compositions, and uses relating thereto

Sugar compositions for treating hemophilia A and/or von Willebrand disease

The present invention relates to a polypeptide comprising a modified von Willebrand Factor (VWF) having a higher Factor VIII binding affinity than non-modified VWF, its pharmaceutical use and method of its preparation.

Von willebrand factor variants having improved factor VIII binding affinity

Growing community of inventors

Marburg, Germany

Stefan Schulte